CD274 and non-small cell lung carcinoma: Unfortunately, we could not assess whether toripalimab plus chemotherapy provided survival benefit independent of PD-L1 expression level in advanced SQ or NSQ NSCLC because the CHOICE-01 publication did not report survival results by PD-L1 expression within each histology (23).